Sabri Medical LLP OC350224 false 2023-04-01 2024-03-31 2024-03-31 The principal activity of the company is that of investments. Digita Accounts Production Advanced 6.30.9574.0 true true OC350224 2023-04-01 2024-03-31 OC350224 2024-03-31 OC350224 core:OtherReservesSubtotal 2024-03-31 OC350224 core:CurrentFinancialInstruments 2024-03-31 OC350224 core:Non-currentFinancialInstruments 2024-03-31 OC350224 core:Non-currentFinancialInstruments core:AfterOneYear 2024-03-31 OC350224 core:WithinOneYear 2024-03-31 OC350224 bus:SmallEntities 2023-04-01 2024-03-31 OC350224 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 OC350224 bus:FilletedAccounts 2023-04-01 2024-03-31 OC350224 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 OC350224 bus:RegisteredOffice 2023-04-01 2024-03-31 OC350224 bus:PartnerLLP1 2023-04-01 2024-03-31 OC350224 bus:PartnerLLP2 2023-04-01 2024-03-31 OC350224 bus:LimitedLiabilityPartnershipLLP 2023-04-01 2024-03-31 OC350224 countries:AllCountries 2023-04-01 2024-03-31 OC350224 2022-04-01 2023-03-31 OC350224 2023-03-31 OC350224 core:OtherReservesSubtotal 2023-03-31 OC350224 core:CurrentFinancialInstruments 2023-03-31 OC350224 core:Non-currentFinancialInstruments 2023-03-31 OC350224 core:Non-currentFinancialInstruments core:AfterOneYear 2023-03-31 OC350224 core:WithinOneYear 2023-03-31 iso4217:GBP xbrli:pure

Registration number: OC350224

Sabri Medical LLP
Unaudited Filleted Financial Statements
for the Year Ended 31 March 2024

Sabri Medical LLP

Contents

Limited liability partnership information | 1
Financial Statements | 2 to 7
Balance Sheet | 2
Notes to the Financial Statements | 4

Sabri Medical LLP

Limited liability partnership information

Designated members | Mrs R Ceballo Montilla Mrs Milagros Del Rosario Montilla Betancourt

Registered office | Ground Floor Hygeia Building 66-68 College Road Harrow Middlesex HA1 1BE

Accountants | Aventus Partners Limited Chartered Certified Accountants Hygeia Building Ground Floor 66-68 College Road Harrow Middlesex HA1 1BE

Sabri Medical LLP

(Registration number: OC350224)
Balance Sheet as at 31 March 2024

| Note | 2024 £ | 2023 £
Current assets |  |  |
Debtors | 3 | 27,467,790 | 25,562,376
Investments |  | 170,587 | 170,587
Cash and short-term deposits |  | 9,179 | 10,499
|  | 27,647,556 | 25,743,462
Creditors: Amounts falling due within one year | 4 | (36,447) | (30,129)
Total assets less current liabilities |  | 27,611,109 | 25,713,333
Creditors: Amounts falling due after more than one year | 5 | (1,876,296) | (1,876,296)
Net assets attributable to members |  | 25,734,813 | 23,837,037
Represented by: |  |  |
Loans and other debts due to members |  |  |
Members' capital classified as a liability |  | (4,906,304) | (4,906,304)
Members’ other interests |  |  |
Members' capital classified as equity |  | 2,116,886 | 2,116,886
Other reserves |  | 28,524,231 | 26,626,455
|  | 30,641,117 | 28,743,341
|  | 25,734,813 | 23,837,037
Total members' interests |  |  |
Loans and other debts due to members |  | (4,906,304) | (4,906,304)
Equity |  | 30,641,117 | 28,743,341
|  | 25,734,813 | 23,837,037

For the year ending 31 March 2024 the limited liability partnership was entitled to exemption from audit under section 477 of the Companies Act 2006, as applied to limited liability partnerships, relating to small entities.

These financial statements have been prepared and delivered in accordance with the provisions applicable to limited liability partnerships subject to the small limited liability partnerships regime. As permitted by section 444 (5A) of the Companies Act 2006, the members have not delivered to the registrar a copy of the Profit and Loss Account.

Sabri Medical LLP

(Registration number: OC350224)
Balance Sheet as at 31 March 2024

The members acknowledge their responsibilities for complying with the requirements of the Companies Act 2006, as applied to limited liability partnerships by the Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008 with respect to accounting records and the preparation of accounts.

The financial statements of Sabri Medical LLP (registered number OC350224) were approved by the Board and authorised for issue on 2 October 2025. They were signed on behalf of the limited liability partnership by:

......................................... Mrs R Ceballo Montilla Designated member | ......................................... Mrs Milagros Del Rosario Montilla Betancourt Designated member |

Sabri Medical LLP

Notes to the Financial Statements for the Year Ended 31 March 2024

1 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with FRS 102 Section 1A 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' ("FRS 102"), the Companies Act 2006 as applied by LLPs and the Statement of Recommended Practice (SORP), Accounting by Limited Liability Partnerships, effective from 1 January 2019, and under the historical cost convention.

General information and basis of accounting

The limited liability partnership is incorporated in the England and Wales under the Limited Liability Partnership Act 2000. The address of the registered office is given on the limited liability partnership information page. The nature of the limited liability partnership’s operations and its principal activities are given in the members’ report.
The functional currency of Sabri Medical LLP is considered to be US dollars because that is the currency of the primary economic environment in which the limited liability partnership operates. Foreign operations are included in accordance with the policies set out below. The presentational currency is GBP£ Pound Sterling and rounded to the nearest £.

Going concern

At the time of approving these financial statements, the members have a reasonable expectation that the LLP has adequate resources to continue in operational existence for the foreseeable future and are willing to provide the necessary financial support as necessary and accordingly these financial statements have been prepared on a going concern basis.

Members' remuneration and division of profits

The SORP recognises that the basis of calculating profits for allocation may differ from the profits reflected through the financial statements prepared in compliance with recommended practice, given the established need to seek to focus profit allocation on ensuring equity between different generations and populations of members.
Members' fixed shares of profits (excluding discretionary fixed share bonuses) and interest earned on members' balances are automatically allocated and, are treated as members' remuneration charged as an expense to the profit and loss account in arriving at profit available for discretionary division among members.
The remainder of profit shares, which have not been allocated until after the balance sheet date, are treated in these financial statements as unallocated at the balance sheet date and included within other reserves.

Foreign currency

Transactions in foreign currencies are recorded at the exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the closing rates at the balance sheet date. All exchange differences are included in the profit and loss account.

Taxation

The taxation payable on the partnership's profits is the personal liability of the members, although payment of such liabilities is administered by the partnership on behalf of its members. Consequently, neither partnership taxation nor related deferred taxation is accounted for in these financial statements. Sums set aside in respect of members' tax obligations are included in the balance sheet within loans and other debts due to members, or are set against amounts due from members as appropriate.

Sabri Medical LLP

Notes to the Financial Statements for the Year Ended 31 March 2024

other taxes policy

Current asset investments

Current asset investments are included at the lower of cost and net realisable value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the limited liability partnership will not be able to collect all amounts due according to the original terms of the receivables.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the limited liability partnership does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Members' interests

Amounts due to members after more than one year comprise provisions for annuities to current members and certain loans from members which are not repayable within twelve months of the balance sheet date.

Financial instruments

Classification

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a finance transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.
Financial assets and liabilities are only offset in the balance sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the limited liability partnership intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Sabri Medical LLP

Notes to the Financial Statements for the Year Ended 31 March 2024

Recognition and Measurement

Debt instruments which meet the following conditions are subsequently measured at amortised cost using the effective interest method:
(a) The contractual return to the holder is (i) a fixed amount; (ii) a positive fixed rate or a positive variable rate; or (iii) a combination of a positive or a negative fixed rate and a positive variable rate.
(b) The contract may provide for repayments of the principal or the return to the holder (but not both) to be linked to a single relevant observable index of general price inflation of the currency in which the debt instrument is denominated, provided such links are not leveraged.
(c) The contract may provide for a determinable variation of the return to the holder during the life of the instrument, provided that (i) the new rate satisfies condition (a) and the variation is not contingent on future events other than (1) a change of a contractual variable rate; (2) to protect the holder against credit deterioration of the issuer; (3) changes in levies applied by a central bank or arising from changes in relevant taxation or law; or (ii) the new rate is a market rate of interest and satisfies condition (a).
(d) There is no contractual provision that could, by its terms, result in the holder losing the principal amount or any interest attributable to the current period or prior periods.
(e) Contractual provisions that permit the issuer to prepay a debt instrument or permit the holder to put it back to the issuer before maturity are not contingent on future events, other than to protect the holder against the credit deterioration of the issuer or a change in control of the issuer, or to protect the holder or issuer against changes in levies applied by a central bank or arising from changes in relevant taxation or law.
(f) Contractual provisions may permit the extension of the term of the debt instrument, provided that the return to the holder and any other contractual provisions applicable during the extended term satisfy the conditions of paragraphs (a) to (c).
Debt instruments that are classified as payable or receivable within one year on initial recognition and which meet the above conditions are measured at the undiscounted amount of the cash or other consideration expected to be paid or received, net of impairment.
With the exception of some hedging instruments, other debt instruments not meeting these conditions are measured at fair value through profit or loss.
Commitments to make and receive loans which meet the conditions mentioned above are measured at cost (which may be nil) less impairment.

Impairment of financial assets

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the limited liability partnership transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the limited liability partnership, despite having retained some significant risks and rewards of ownership, has transferred control of the asset to another party and the other party has the practical ability to sell the asset in its entirety to an unrelated third party and is able to exercise that ability unilaterally and without needing to impose additional restrictions on the transfer.
Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

Sabri Medical LLP

Notes to the Financial Statements for the Year Ended 31 March 2024

2 | Particulars of employees

The average number of persons employed by the limited liability partnership during the year was 2 (2023 - 2).

3 | Debtors

| 2024 £ | 2023 £
Trade debtors | 14,468,518 | 14,468,518
Other debtors | 20,588 | 20,588
Prepayments and accrued income | 12,978,684 | 11,073,270
Total current trade and other debtors | 27,467,790 | 25,562,376

4 | Creditors: Amounts falling due within one year

| 2024 £ | 2023 £
Trade creditors | 6,318 | 2,004
Other creditors | 25,929 | 19,725
Accruals and deferred income | 4,200 | 8,400
| 36,447 | 30,129

5 | Creditors: Amounts falling due after more than one year

| 2024 £ | 2023 £
Other creditors | 1,876,296 | 1,876,296

6 | Control

The members are the controlling party by virtue of their controlling interest in the limited liability partnership. The ultimate controlling party is the same as the controlling party.